Skip to main content

Table 2 Clinical manifestations at the last follow-up in AO, RO, and MO subgroups

From: Elucidation of predictors of disease progression in patients with relapsing polychondritis at the onset: potential impact on patient monitoring

  Auricular involvement, n, (% of the group)a Respiratory involvement, n, (%)b Ocular involvement, n, (%)c Nasal involvement, n, (%) Joint involvement, n, (%) Inner ear involvement, n, (%)c Skin involvement, n, (%) CNS involvement, n, (%)d Renal involvement, n, (%) Cardiovascular involvement, n, (%)d
All 229 patients 182, (79%) 112, (49%) 113, (49%) 91, (40%) 90, (39%) 64, (30%) 32, (14%) 28, (12%) 18, (7.9%) 16, (7.0%)
AO, 135 patients 135, (100%) 44, (33%) 60, (44%) 49, (36%) 60, (44%) 32, (24%) 19, (14%) 17, (13%) 10, (7.4%) 10, (7.4%)
RO, 48 patients 9, (19%) 48, (100%) 17, (35%) 25, (52%) 13, (27%) 8, (17%) 5, (10%) 1, (2.1%) 2, (4.2%) 0, (0.0%)
MO, 46 patients 38, (83%) 20, (43%) 34, (74%) 15, (33%) 16, (35%) 24, (52%) 8, (17%) 10, (21%) 6, (13%) 6, (13%)
  1. aThe incidence was significantly higher in AO patients than that in RO patients and that in MO patients. The incidence was significantly higher in MO patients than that in RO patients
  2. bThe incidence was significantly higher in RO patients than that in AO patients and that in MO patients
  3. cThe incidence was significantly higher in MO patients than that in AO patients and that in RO patients
  4. dThe incidence was significantly higher in MO patients than that in RO patients